Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Authors :: Marmorino, F.
Cremolini, C.
Loupakis, F.
Antoniotti, C.
Barbara, C.
Dargenio, F.
Miraglio, E.
Masi, G.
Salvatore, L.
Marta Schirripa
Borelli, B.
Marcucci, L.
Antonuzzo, L.
Chiara, S.
Banzi, C.
Amoroso, D.
Bonetti, A.
Martignetti, A.
Paris, M.
Boni, L.
Tomcikova, D.
Falcone, A.
Source :: Publons, ResearcherID

Tools